Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Single-center Randomized Controlled Trial of Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma Treated With First-line Gemcitabine Plus Cisplatin

NCT03389438 is registered in ClinicalTrials.gov with Beijing Huanxing Cancer Hospital as lead sponsor.

NCT NCT03389438
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03389438 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Single-center Randomized Controlled Trial of Autologous Cellular Immunotherapy in Patients With Metastatic Bladder Urothelial Carcinoma Treated With First-line Gemcitabine Plus Cisplatin
Lead sponsor
Beijing Huanxing Cancer Hospital
Phase
Phase 2
Overall status
Terminated
Start date
February 26, 2018
Completion date
October 31, 2021
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

urinary bladder neoplasm